IBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ImmunityBio Inc (IBRX) is not a strong buy at the moment for a beginner, long-term investor. While the company has shown significant revenue growth and positive analyst ratings, the ongoing class action lawsuits and recent stock price decline present significant risks. The technical indicators and options data do not suggest a strong entry point currently. It is better to wait for more clarity on legal outcomes and stabilization in stock performance before considering an investment.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 44.862, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 7.274, with support at 6.827 and resistance at 7.721, suggesting limited immediate upside potential.
Analysts have issued positive ratings with increased price targets, citing strong revenue growth and regulatory approvals for Anktiva.
The company's 2025 Q4 revenue increased by 406.95% YoY, showcasing significant growth potential.
Multiple class action lawsuits alleging misleading statements about Anktiva's efficacy and FDA warnings have created uncertainty and potential legal liabilities.
The stock has declined significantly in regular market trading, down 6.81%, with limited immediate recovery signs.
EPS dropped by 25% YoY, and gross margin declined slightly.
In 2025/Q4, revenue surged by 406.95% YoY to $38.29M, indicating strong top-line growth. However, net income remains negative at -$61.94M, with a modest improvement of 4.7% YoY. EPS dropped by 25% YoY to -0.06, and gross margin slightly declined to 99%. The financials show growth potential but also highlight profitability concerns.
Analysts are bullish on the stock, with recent ratings from BTIG, Piper Sandler, and H.C. Wainwright assigning Buy ratings and raising price targets to $13, $12, and $15, respectively. Analysts cite strong revenue growth, regulatory approvals, and commercial execution as key drivers for future appreciation.
